Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.

Sonia JaramilloLucian Le CornetMarkus KratzmannJohannes KrisamMartin GörnerMathias HänelChristoph RölligMaxi WassSebastian SchollMark RinghofferAlexander ReichartBjörn SteffenSabine KayserJan-Henrik MikeschKerstin Schaefer-EckartJörg SchubertThomas GeerSonja MartinMeinhard KieserTim SauerKatharina KriegsmannMichael HundemerHubert ServeMartin BornhäuserCarsten Müller-TidowRichard F Schlenk

Published in: Trials (2023)

ClinicalTrials.gov NCT03989713; EudraCT Number: 2018-002675-17.

Keyphrases

acute myeloid leukemia
high dose
double blind
placebo controlled
open label
phase iii
clinical trial
stem cell transplantation
low dose
allogeneic hematopoietic stem cell transplantation
phase ii
study protocol
cross sectional
acute lymphoblastic leukemia
randomized controlled trial